-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Genetics and MRD

Program: Scientific Workshops @ ASH
Session: Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, and CyTOF: Diverse Ways of Detection
Thursday, December 3, 2020, 8:32 AM-9:12 AM

Martin F. Kaiser, MD, FRCP, FRCPath

The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom

Disclosures: Kaiser: Bristol-Myers Squibb, Chugai, Janssen, Amgen, Takeda, Celgene, AbbVie, Karyopharm, GlaxoSmithKline: Consultancy; Bristol-Myers Squibb, Takeda: Other: Travel expenses; Janssen, Amgen, Celgene, Bristol-Myers Squibb, Takeda: Honoraria; Bristol-Myers Squibb/Celgene, Janssen, Karyopharm: Research Funding.

See more of: Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, and CyTOF: Diverse Ways of Detection
See more of: Scientific Workshops @ ASH
<< Previous Presentation | Next Presentation >>